Eric Fink is CHRO at Global Blood Therapeutics, Inc. (GBT). They have made 3 open-market trades across 1 company since 2020, most recently 2021-05-10.
CIK 0001784038
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
1 open-market purchase totalling $19K since 2021, against 2 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| GBT | 5,161 | $353K |
Shares reported on the most recent Form 4, priced at the 2021-05-10 close.
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.